Patient behaviors associated with optimum glycemic outcomes with sensor-augmented pump therapy: Insights from the star 3 study

Endocrine Practice

Volumn 21, Issue 1, 2015, Pages 41-45

  Tanenberg, Robert J ^a   Welsh, John B ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; ADULT DISEASE; AGE DISTRIBUTION; ARTICLE; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HEALTH BEHAVIOR; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MAJOR CLINICAL STUDY; PEDIATRICS; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; ANALYSIS; BLOOD; CHILD; DIABETES MELLITUS, TYPE 1; INSULIN INFUSION; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; MIDDLE AGED;

EID: 84921851867     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP14187.OR     Document Type: Article

References (10)

1. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010;12:249-255.
2. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-320.
3. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34:2403-2405.
4. Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther. 2012;14:644-647.
5. Rubin RR, Peyrot M. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. Diabetes Technol Ther. 2011;14:143-151.
6. Evans JM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ. 1999;319:83-86.
7. Enander R, Gundevall C, Strömgren A, Chaplin J, Hanas R. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2012;13:545-551.
8. Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther. 2003;5:365-369.
9. Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol. Sep 2011;5:1137-1141.
10. Scheiner G, Sobel RJ, Smith DE, et al. Insulin pump therapy: guidelines for successful outcomes. Diabetes Educ. 2009;35 Suppl 2:29S-41S; quiz 28S, 42S-43S.